力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002393 力生制药

已收盘 05-06 15:00:00

{"stockData":{"symbol":"002393","market":"SZ","secType":"STK","nameCN":"力生制药","latestPrice":26.42,"timestamp":1714979004000,"preClose":25.45,"halted":0,"volume":3522848,"delay":0,"floatShares":182000000,"shares":184000000,"eps":2.0326,"marketStatus":"已收盘","marketStatusCode":5,"change":0.97,"latestTime":"05-06 15:00:00","open":25.78,"high":26.42,"low":25.55,"amount":91497200,"amplitude":0.0342,"askPrice":26.42,"askSize":33,"bidPrice":26.41,"bidSize":13,"shortable":0,"etf":0,"ttmEps":2.0326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715045400000},"adr":0,"adjPreClose":25.45,"symbolType":"stock","openAndCloseTimeList":[[1714959000000,1714966200000],[1714971600000,1714978800000]],"highLimit":28,"lowLimit":22.91,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":184244992,"pbRate":0.94,"roa":"--","roe":"1.2%","epsLYR":1.97,"committee":-0.493333,"marketValue":4868000000,"floatMarketCap":4820000000,"peRate":12.998131,"changeRate":0.0381,"turnoverRate":0.0193,"status":0},"requestUrl":"/m/hq/s/002393/wiki","defaultTab":"wiki","newsList":[{"id":"2430492465","title":"天津发展(00882)：力生制药一季度归母净利润5915.56万元 同比增加27.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430492465","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430492465?lang=zh_cn&edition=full","pubTime":"2024-04-25 06:26","pubTimestamp":1713997563,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天津发展(00882)发布公告，该公司附属力生制药截至2024年3月31日止3个月取得营业总收入3.65亿元，同比增加8.71%;归属于母公司所有者的净利润5915.56万元，同比增加27.22%;基本每股收益0.32元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109444.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429484683","title":"力生制药最新公告：一季度净利润5915.56万元 同比增长27.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429484683","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429484683?lang=zh_cn&edition=full","pubTime":"2024-04-24 16:51","pubTimestamp":1713948691,"startTime":"0","endTime":"0","summary":"力生制药公布2024年一季度报告，报告期营业收入3.65亿元，同比增长8.71%；归属于上市公司股东的净利润5915.56万元，同比增长27.22%；基本每股收益0.32元。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400033662.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429851894","title":"力生制药(002393.SZ)发布一季度业绩，净利润5915.56万元 同比增加27.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429851894","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429851894?lang=zh_cn&edition=full","pubTime":"2024-04-24 15:51","pubTimestamp":1713945087,"startTime":"0","endTime":"0","summary":"智通财经APP讯，力生制药(002393.SZ)发布2024年一季度报告，报告期内公司实现营业收入3.65亿元，同比增加8.71%;归属于上市公司股东的净利润5915.56万元，同比增加27.22%;归属于上市公司股东的扣除非经常性损益的净利润5887.36万元，同比增加29.71%;基本每股收益0.32元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108355.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2417735869","title":"力生制药(002393.SZ)：替格瑞洛原料药通过上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2417735869","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2417735869?lang=zh_cn&edition=full","pubTime":"2024-03-07 16:03","pubTimestamp":1709798580,"startTime":"0","endTime":"0","summary":"力生制药(002393.SZ)公告，近日，公司收到国家药品监督管理局颁发的关于替格瑞洛原料药《化学原料药上市申请批准通知书》，该品种通过化学原料药上市申请。据悉，替格瑞洛的适应症如下：替格瑞洛与阿司匹林(ASA)联合用药适用于预防成人患者的动脉粥样硬化血栓形成事件、急性冠状动脉综合征(ACS)、心肌梗塞(MI)病史和发生动脉粥样硬化血栓形成的高风险事件。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-07/doc-inamnsyk7897378.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-07/doc-inamnsyk7897378.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2409140077","title":"力生制药(002393.SZ)：硫酸沙丁胺醇片通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2409140077","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2409140077?lang=zh_cn&edition=full","pubTime":"2024-02-05 12:07","pubTimestamp":1707106020,"startTime":"0","endTime":"0","summary":"力生制药(002393.SZ)公告，公司收到国家药品监督管理局颁发的关于硫酸沙丁胺醇片2mg规格的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。其适应症为：用于缓解支气管哮喘或喘息型支气管炎伴有支气管痉挛的病症。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-05/doc-inafxzvp7671228.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-05/doc-inafxzvp7671228.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2404590048","title":"力生制药靠资产处置最高预盈3.8亿 货币资金超21亿负债率仅16.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2404590048","media":"市场资讯","top":-1,"share":"https://www.laohu8.com/m/news/2404590048?lang=zh_cn&edition=full","pubTime":"2024-01-19 09:35","pubTimestamp":1705628100,"startTime":"0","endTime":"0","summary":"　　业绩短暂承压后，力生制药2023年盈利能力大幅提升。　　1月17日晚间，力生制药发布业绩预告，2023年预计实现归母净利润3.4亿元至3.8亿元，同比增长263.2%至305.9%。　　长江商报记者注意到，力生制药的负债较少，自2018年末以来，公司长期借款为零，资产负债率常年维持在20%以下，截至2023年9月末，公司的资产负债率为16.53%；与此同时，公司的货币资金呈增长趋势，截至2023年三季度末达21.25亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-01-19/doc-inaczksk0966710.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-01-19/doc-inaczksk0966710.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2404397643","title":"力生制药(002393.SZ)发预增，预计2023年度净利润3.4亿元-3.8亿元，同比大增263.2%-305.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2404397643","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2404397643?lang=zh_cn&edition=full","pubTime":"2024-01-17 19:22","pubTimestamp":1705490520,"startTime":"0","endTime":"0","summary":"力生制药(002393.SZ)发布公告，公司预计2023年度归属于上市公司股东的净利润为3.4亿元-3.8亿元，同比增长263.2%-305.9%。公司积极推动营销变革，调整产品销售结构，带动公司综合毛利率水平提升，同时强化预算管理和成本控制，压缩各项可控成本费用，公司成本费用均有一定幅度下降，扣除非经常性损益后的净利润实现较大幅度增长。此外，2023年度公司处置黄河道厂区土地，获得土地补偿款24790万元，受该因素影响，2023年度归属于上市公司股东的净利润有较大增幅。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-17/doc-inacvtrx3085442.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-17/doc-inacvtrx3085442.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2389646851","title":"力生制药(002393.SZ)拟2500万元参设投资基金 以大健康领域核心进行布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2389646851","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2389646851?lang=zh_cn&edition=full","pubTime":"2023-12-08 20:34","pubTimestamp":1702038840,"startTime":"0","endTime":"0","summary":"力生制药(002393.SZ)公告，公司拟与博正资本投资有限公司、天津市津嘉产业投资运营有限公司等共同设立天津博正力生大健康私募股权投资基金(有限合伙)(暂定名)。本次交易公司及全资子公司天津力生投资管理有限公司共出资2500万元。该基金将以大健康领域核心，重点投向小分子创新药、生物药、高端制剂、高端器械、医疗服务等领域。据悉，本次投资有利于推动公司逐步实现业务结构的优化升级，增强公司的持续经营实力。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-08/doc-imzxiiin8007832.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-12-08/doc-imzxiiin8007832.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2382321267","title":"力生制药：盐酸普萘洛尔片通过仿制药一致性评价 有利于提升该药品市场竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2382321267","media":"财华社","top":-1,"share":"https://www.laohu8.com/m/news/2382321267?lang=zh_cn&edition=full","pubTime":"2023-11-09 15:27","pubTimestamp":1699514851,"startTime":"0","endTime":"0","summary":"力生制药（002393）公告称，公司近日收到国家药品监督管理局颁发的关于盐酸普萘洛尔片10mg规格的《药品补充申请批准通知书》（批件号：2023B05466），该药品通过仿制药质量和疗效一致性评价，有利于提升该药品市场竞争力。","market":"us","thumbnail":"https://www.finet.hk/images/news_default.jpg","type":0,"news_type":0,"thumbnails":["https://www.finet.hk/images/news_default.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/654c8af253243c0783753b3a","is_publish_highlight":false,"gpt_icon":0},{"id":"2382268549","title":"力生制药(002393.SZ)：盐酸普萘洛尔片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2382268549","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2382268549?lang=zh_cn&edition=full","pubTime":"2023-11-09 11:55","pubTimestamp":1699502100,"startTime":"0","endTime":"0","summary":"力生制药发布公告，近日，公司收到国家药品监督管理局颁发的关于盐酸普萘洛尔片10mg规格的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。盐酸普萘洛尔片适应症：1.作为二级预防，降低心肌梗死死亡率。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-11-09/doc-imztytuq0362170.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2023-11-09/doc-imztytuq0362170.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-04-23","address":"天津市西青区西青经济技术开发区赛达北一道16号","stockEarnings":[{"period":"1week","weight":0.046},{"period":"1month","weight":0.0237},{"period":"3month","weight":0.1826},{"period":"6month","weight":-0.0436},{"period":"1year","weight":0.0737},{"period":"ytd","weight":-0.0249}],"companyName":"天津力生制药股份有限公司","boardCode":"AI0027","perCapita":"9734股","boardName":"医药制造业","registeredCapital":"18424万元","compareEarnings":[{"period":"1week","weight":0.0274},{"period":"1month","weight":0.0209},{"period":"3month","weight":0.1134},{"period":"6month","weight":0.0317},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":0.0437}],"survey":"　　天津力生制药股份有限公司主营业务为医药产品研发、生产和销售。公司主要产品有主胶囊、片剂、针剂等。","serverTime":1714985977520,"listedPrice":45,"stockholders":"18744人(较上一季度增加0.84%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"力生制药,002393,力生制药股票,力生制药股票老虎,力生制药股票老虎国际,力生制药行情,力生制药股票行情,力生制药股价,力生制药股市,力生制药股票价格,力生制药股票交易,力生制药股票购买,力生制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"力生制药(002393)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供力生制药(002393)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}